139 related articles for article (PubMed ID: 16319911)
1. Multidose risperidone treatment evaluated in a rodent model of tardive dyskinesia.
Gao XM; Cooper T; Suckow RF; Tamminga CA
Neuropsychopharmacology; 2006 Sep; 31(9):1864-8. PubMed ID: 16319911
[TBL] [Abstract][Full Text] [Related]
2. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats.
Turrone P; Remington G; Kapur S; Nobrega JN
Psychopharmacology (Berl); 2003 Jan; 165(2):166-71. PubMed ID: 12417967
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
Shireen E; Naeem S; Inam QU; Haleem DJ
Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196
[TBL] [Abstract][Full Text] [Related]
4. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
Gao XM; Sakai K; Tamminga CA
Neuropsychopharmacology; 1998 Nov; 19(5):428-33. PubMed ID: 9778664
[TBL] [Abstract][Full Text] [Related]
5. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Haleem DJ; Samad N; Haleem MA
Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
[TBL] [Abstract][Full Text] [Related]
6. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
[TBL] [Abstract][Full Text] [Related]
7. Lipoic acid and haloperidol-induced vacuous chewing movements: Implications for prophylactic antioxidant use in tardive dyskinesia.
Lister J; Andreazza AC; Navaid B; Wilson VS; Teo C; Nesarajah Y; Wilson AA; Nobrega JN; Fletcher PJ; Remington G
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jan; 72():23-29. PubMed ID: 27565433
[TBL] [Abstract][Full Text] [Related]
8. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol.
Egan MF; Hurd Y; Ferguson J; Bachus SE; Hamid EH; Hyde TM
Psychopharmacology (Berl); 1996 Oct; 127(4):337-45. PubMed ID: 8923569
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
11. Haloperidol versus risperidone on rat "early onset" vacuous chewing.
Marchese G; Bartholini F; Casu MA; Ruiu S; Casti P; Congeddu E; Tambaro S; Pani L
Behav Brain Res; 2004 Feb; 149(1):9-16. PubMed ID: 14739005
[TBL] [Abstract][Full Text] [Related]
12. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Naidu PS; Kulkarni SK
Behav Pharmacol; 2001 Jun; 12(3):209-16. PubMed ID: 11485057
[TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
[TBL] [Abstract][Full Text] [Related]
14. Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.
Meshul CK; Andreassen OA; Allen C; Jørgensen HA
Psychopharmacology (Berl); 1996 Jun; 125(3):238-47. PubMed ID: 8815959
[TBL] [Abstract][Full Text] [Related]
15. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
16. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia.
Hashimoto T; Ross DE; Gao XM; Medoff DR; Tamminga CA
Psychopharmacology (Berl); 1998 May; 137(2):107-12. PubMed ID: 9629996
[TBL] [Abstract][Full Text] [Related]
17. Neuroleptic-induced vacuous chewing movements in rodents: incidence and effects of long-term increases in haloperidol dose.
Egan MF; Hyde TM; Kleinman JE; Wyatt RJ
Psychopharmacology (Berl); 1995 Jan; 117(1):74-81. PubMed ID: 7724705
[TBL] [Abstract][Full Text] [Related]
18. Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
Egan MF; Ferguson JN; Hyde TM
Brain Res Bull; 1995; 38(4):355-63. PubMed ID: 8535858
[TBL] [Abstract][Full Text] [Related]
19. Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes.
Daya RP; Tan ML; Sookram CD; Skoblenick K; Mishra RK
Brain Res; 2011 Sep; 1412():28-36. PubMed ID: 21816389
[TBL] [Abstract][Full Text] [Related]
20. Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing.
Marchese G; Casu MA; Bartholini F; Ruiu S; Saba P; Gessa GL; Pani L
Eur J Neurosci; 2002 Apr; 15(7):1187-96. PubMed ID: 11982629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
